Signs deal for product that improves the medical industry
Austin, Texas, April 3, 2024 /PRNewswire/ — Alafair Biosciences, Inc., a leading innovator in medical device development and commercialization, today announced that its flagship product, VersaWrap®, has received a transformational technology agreement from Vizient.,Co., Ltd The nation's largest provider-led healthcare performance improvement company.contract is valid April 1, 2024was awarded based on VersaWrap's recommendation by hospital experts on one of Vizient's customer-driven councils. This agreement demonstrates unique qualities to Vizient provider customers that have the potential to bring improvements to the healthcare industry.
Innovative technology contracts are recommended after review and interaction with products submitted through Vizient's Innovative Technology program. Vizient's customer-driven councils identify technologies that have the potential to enhance clinical care, patient safety, health care worker safety, or improve healthcare organization operations.
VersaWrap is a hyaluronic acid (HA) and alginate hydrogel that allows tissue to glide and remain unbound, reducing reoperations and improving patient outcomes. Designed to protect injuries during healing, VersaWrap is the only Class II medical device cleared by the FDA for use on tendons, ligaments, skeletal muscles, peripheral nerves (including nerve roots), and It is the only tendon/nerve hydrogel that can be implanted as a nerve hydrogel. As a sheet or extrudable gel. While most competing products are collagen-based (bovine, porcine, and human placental tissue), VersaWrap is composed of hyaluronic acid (HA) and plant-based alginate and contains no human or animal ingredients.
“We are truly honored that VersaWrap has been recognized and awarded this outstanding innovative technology contract.” john joypriteno, President and CEO of Alafair Biosciences. “This agreement is a great opportunity to increase access to her VersaWrap to her Vizient customers, clinicians and patients across the United States.”
“We congratulate Alafair Biosciences on achieving this peer designation status.” kelly flaherty, Senior Director Contract Services and Vizient Innovative Technology Program Leader. “Our customer council determined that VersaWrap deserves this designation because it has the potential to make a real difference in the healthcare industry.”
Vizient represents a diverse customer base that includes academic medical centers, pediatric facilities, community hospitals, integrated care delivery networks, non-acute care providers, and has a portfolio that represents more. $130 billion In terms of annual purchase volume.through it innovative technology program, Vizient works with customer-led councils and task forces to evaluate products that have the potential to bring true innovation to healthcare. Vizient may award contracts outside of the competitive bidding cycle to products deemed worthy of innovative technology designation.
For more information, please contact John Joyoprayitno at jjoyo@alafairbiosciences.com.
About Alafair Biosciences
Alafair is a privately held medical device company that develops and markets a portfolio of innovative products based on proprietary hydrogel technology. Alafair's mission is to improve surgeon experience and patient outcomes by preventing unnecessary soft tissue entrapment in all surgical applications. Alafair products are sold worldwide through a distributed network of independent distributors. America.
About VersaWrap®
VersaWrap is an FDA-cleared medical device implant (not tissue) containing hyaluronic acid (HA) and alginate that provides a gelatinous wrap around peripheral nerves, tendons, and surrounding tissues such as ligaments and skeletal muscle. With VersaWrap, tissue slips and remains unfixed, reducing reoperations and improving patient outcomes.
View original content to download multimedia: https://www.prnewswire.com/news-releases/alafair-biosciences-receives-innovative-technology-contract-from-vizient-for-versawrap- 302106479.html
SOURCE Alafair Biosciences, Inc.
